Brought to you by 
BMS, uniQure sign cardiovascular gene therapy deal; deal to terminate in 2023
29 Nov 2022
Executive Summary
In its first major gene therapy deal, Bristol-Myers Squibb Co. received exclusive rights to uniQure NV's gene therapy technology for use against ten cardiovascular targets, including the calcium-binding protein S100A1 (BMS will have rights to the preclinical S100A1 program for congestive heart failure).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, uniQure sign cardiovascular gene therapy deal; deal to terminate in 2023
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice